Table 1.
Patient characteristics: ITT/Safety Population (N = 214)
| Age (yrs), mean ± SD | 37 ± 12 |
| Female, n (%) | 111 (52) |
| Race, n (%) | |
| White | 178 (83) |
| Black | 4 (2) |
| Other | 36 (17) |
| Epilepsy duration (years), mean ± SDa | 19 ± 14 |
| Baseline seizure frequency (average seizures/28 days), mediana | 6.5 |
| Concomitant AEDs, n (%)a | |
| 1 AED | 72 (34) |
| 2 AEDs | 118 (55) |
| ≥3 AEDs | 24 (11) |
| Valproate | 111 (52) |
| Carbamazepine | 78 (36) |
| Lamotrigine | 53 (24) |
| Topiramate | 43 (20) |
| Levetiracetam | 35 (16) |
| Barbiturates | 16 (7) |
| Gabapentin/pregabalin | 15 (7) |
| Other | 24 (11) |
a
At baseline of core double‐blind (PROSPER) study.